Compare Eli Lilly And Co (LLY) vs Global X NASDAQ 100 Covered Call ETF (QYLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Eli Lilly And Co vs Global X NASDAQ 100 Covered Call ETF — how do they compare? Eli Lilly And Co trades at $1,179.27 (market cap $1.04T), while Global X NASDAQ 100 Covered Call ETF trades at $18.69 (market cap $8.49B). The key difference: Eli Lilly And Co is far larger — about 122.5× Global X NASDAQ 100 Covered Call ETF's market cap, and Eli Lilly And Co pays a 0.59% dividend while Global X NASDAQ 100 Covered Call ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Eli Lilly And Co for 93 Days and Global X NASDAQ 100 Covered Call ETF for 51 Days on average.
| LLY | QYLD | |
|---|---|---|
Market Cap | $1.04T | $8.49B |
Volume | 3,064,878 | 2,913,938 |
Sector | Health | Income / Options Overlay |
52-Week High | $1.28K | $18.68 |
52-Week Low | $799.57 | $16.70 |
Typical Hold Time | 93 Days | 51 Days |
Enterprise Value | $1.09T | — |
Dividend Yield | 0.59% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Eli Lilly (LLY) trades at $1,169.93, down 1.58% on the day, but maintains strong bullish momentum with consistent earnings beats and robust revenue growth. The company demonstrates exceptional profitability with 83.4% gross margins and 33.53% net income margins, supported by dominant positioning in weight-loss and diabetes treatments. Recent clinical trial successes for next-generation drugs and expanded FDA approvals reinforce growth prospects.
LLY presents compelling growth potential with analyst consensus target of $1,350 representing 15% upside, though elevated valuations (P/E 39.26) and increasing competition in obesity drugs pose risks. Strong institutional support (73% buy ratings) and positive pipeline developments support continued momentum, but investors should monitor execution risks and market saturation concerns.
QYLD trades at $18.66, showing minimal daily movement with a slight decline of -0.11%. The ETF maintains a consistent monthly dividend distribution of $0.18 per share, with technical indicators showing mixed signals—bullish moving averages but bearish oscillators including overbought RSI readings. Recent news highlights QYLD's high yield strategy but raises concerns about long-term capital erosion and tax implications.
QYLD offers high monthly income through covered call strategies but faces significant risks from capped upside potential and principal erosion. The ETF's distribution sustainability depends on Nasdaq volatility, with recent articles warning about declining option premiums. Investors should weigh the trade-off between immediate income and long-term capital preservation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Eli Lilly And Co
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer
Read more on LLY →About Global X NASDAQ 100 Covered Call ETF
QYLD is an ETF that follows a covered call strategy on the NASDAQ 100 Index. The fund holds a long position in the stocks of the NASDAQ 100 and simultaneously writes (sells) call options on the index. The primary goal is to generate monthly income from the option premiums. This strategy can reduce portfolio volatility and provide income, but it limits potential capital appreciation from a significant rise in the NASDAQ 100 Index.
Read more on QYLD →
